An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Cerus Corporation to Participate in Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Cerus Corporation (NASDAQ: CERS) announced that its COO, Vivek Jayaraman, will participate in two upcoming conferences. He is scheduled to present at the Stifel 2022 Healthcare Conference on November 16 at 1:50 p.m. EST in New York and at the Stephens Annual Investment Conference on November 17 at 12:00 p.m. EST in Nashville, TN. To access the webcasts, visit ir.cerus.com. Cerus is focused on ensuring the safety of the global blood supply with its INTERCEPT Blood System, already approved in various regions.
Positive
None.
Negative
None.
CONCORD, Calif.--(BUSINESS WIRE)--
Cerus Corporation (Nasdaq: CERS) announced today that Vivek Jayaraman, Cerus’ chief operating officer, is scheduled to participate in two conferences:
The Stifel 2022 Healthcare Conference on Wednesday, November 16th at 1:50 p.m. EST, at the Lotte New York Palace Hotel.
The Stephens Annual Investment Conference on Thursday, November 17th, at 12:00 p.m. EST, at the Grand Hyatt in Nashville, TN.
To listen to webcasts of these presentations, please visit the investor relations section of Cerus’ website at: ir.cerus.com.
ABOUT CERUS
Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE Mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of INTERCEPT Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.
What events is Cerus Corporation participating in November 2022?
Cerus Corporation is participating in the Stifel 2022 Healthcare Conference on November 16 and the Stephens Annual Investment Conference on November 17.
When is Vivek Jayaraman presenting at the Stifel 2022 Healthcare Conference?
Vivek Jayaraman will present at the Stifel 2022 Healthcare Conference on November 16 at 1:50 p.m. EST.
Where is the Stephens Annual Investment Conference being held?
The Stephens Annual Investment Conference is being held at the Grand Hyatt in Nashville, TN on November 17.
How can I listen to Cerus Corporation's conference presentations?
You can listen to the webcasts of Cerus Corporation's presentations by visiting their investor relations website at ir.cerus.com.
What is the focus of Cerus Corporation's technologies?
Cerus Corporation focuses on safeguarding the global blood supply with its INTERCEPT Blood System, which includes pathogen reduction technologies for blood components.
